Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...

In both TEASE-1 and TEASE-3, gildeuretinol demonstrated a favorable safety and tolerability profile. There were no adverse ...

Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window GA lesions, which form on the retina due to degeneration of pigment epithelium and photoreceptors, significantly impact ...

Ocugen (OCGN) announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa ...

In TEASE-1, a placebo-controlled, double-masked, randomized 24-month study in patients with Stargardt disease, gildeuretinol slowed the growth rate of atrophic retinal lesions area (square root ...

Belite Bio, Inc. ( NASDAQ: BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief ...

Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...

Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX ...

Clinical trials, TEASE-1 and TEASE-3, showed gildeuretinol significantly slowed retinal lesion growth and stabilized visual ...